Evidence map›Paper›PMID 30857410›Full record

ArticleCirculation. Cardiovascular quality and outcomes2019

Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy.

Tony Duan, Pranav Rajpurkar, Dillon Laird, Andrew Y Ng, Sanjay Basu

Retracted 2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyRetracted Publication
In one paragraph

Article in Circulation. Cardiovascular quality and outcomes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It reports registered trial NCT00000620. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000620 phase3completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Ran1999Enrolled10,251Registered outcomes6Posted comparisons6ConditionsAtherosclerosis, Cardiovascular Diseases, Coronary Disease, Diabetes MellitusArmsAnti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Open the trial in the graph
NCT01206062 nacompletednot on this map

Systolic Blood Pressure Intervention Trial

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2010 to 2019Enrolled9,361ConditionsHypertensionArmsIntensive control of SBP, Standard control of SBP
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Survey and Evaluation of Hypertension Machine Learning Research.Journal of the American Heart Association · 2023
    Article
  17. Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve.Journal of cardiovascular development and disease · 2023
    Review
  18. Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants.Medical decision making : an international journal of the Society for Medical Decision Making · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tony DuanDepartment of Computer Science (T.D., P.R., D.L., A.Y.N.), Stanford University, Stanford, CA.
Pranav RajpurkarDepartment of Computer Science (T.D., P.R., D.L., A.Y.N.), Stanford University, Stanford, CA.
Dillon LairdDepartment of Computer Science (T.D., P.R., D.L., A.Y.N.), Stanford University, Stanford, CA.
Andrew Y NgDepartment of Computer Science (T.D., P.R., D.L., A.Y.N.), Stanford University, Stanford, CA.
Sanjay BasuCenter for Primary Care and Outcomes Research and Center for Population Health Sciences, Departments of Medicine and of Health Research and Policy (S.B.), Stanford University, Stanford, CA.
Stanford University · USStanford Health Care · US

Funding

Applying statistical learning tools to personalize cardiovascular treatmentR01HL144555 · NHLBI · STANFORD UNIVERSITY · PI SHAH, NIGAM H · 2019 to 2022
$3.0M
Developing data tools to reduce CVD disparities via Health Information ExchangesR21MD012867 · NIMHD · STANFORD UNIVERSITY · PI ZOU, JAMES · 2018 to 2019
$420k
NHLBI NIH HHS R01 HL144555NIMHD NIH HHS R21 MD012867
6 · The paper itself

Abstract

backgroundThe absolute risk reduction (ARR) in cardiovascular events from therapy is generally assumed to be proportional to baseline risk-such that high-risk patients benefit most. Yet newer analyses have proposed using randomized trial data to develop models that estimate individual treatment effects. We tested 2 hypotheses: first, that models of individual treatment effects would reveal that benefit from intensive blood pressure therapy is proportional to baseline risk; and second, that a machine learning approach designed to predict heterogeneous treatment effects-the X-learner meta-algorithm-is equivalent to a conventional logistic regression approach. METHODS AND

resultsWe compared conventional logistic regression to the X-learner approach for prediction of 3-year cardiovascular disease event risk reduction from intensive (target systolic blood pressure <120 mm Hg) versus standard (target <140 mm Hg) blood pressure treatment, using individual participant data from the SPRINT (Systolic Blood Pressure Intervention Trial; N=9361) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure; N=4733) trials. Each model incorporated 17 covariates, an indicator for treatment arm, and interaction terms between covariates and treatment. Logistic regression had lower C statistic for benefit than the X-learner (0.51 [95% CI, 0.49-0.53] versus 0.60 [95% CI, 0.58-0.63], respectively). Following the logistic regression's recommendation for individualized therapy produced restricted mean time until cardiovascular disease event of 1065.47 days (95% CI, 1061.04-1069.35), while following the X-learner's recommendation improved mean time until cardiovascular disease event to 1068.71 days (95% CI, 1065.42-1072.08). Calibration was worse for logistic regression; it over-estimated ARR attributable to intensive treatment (slope between predicted and observed ARR of 0.73 [95% CI, 0.30-1.14] versus 1.06 [95% CI, 0.74-1.32] for the X-learner, compared with the ideal of 1). Predicted ARRs using logistic regression were generally proportional to baseline pretreatment cardiovascular risk, whereas the X-learner observed-correctly-that individual treatment effects were often not proportional to baseline risk.

conclusionsPredictions for individual treatment effects from trial data reveal that patients may experience ARRs not simply proportional to baseline cardiovascular disease risk. Machine learning methods may improve discrimination and calibration of individualized treatment effect estimates from clinical trial data. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov . Unique identifiers: NCT01206062; NCT00000620.

Indexed as

Data MiningMachine LearningAgedAntihypertensive AgentsBlood PressureFemaleHumansHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTreatment OutcomeAntihypertensive Agentsblood pressurecalibrationcardiovascular diseasemachine learningrisk factors

Identifiers

PMID30857410
PMCPMC6756170
OpenAlexW2921504248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.